CONFLITO DE INTERESSES DECLARADO POR TODOS OS PROFISSIONAIS DE SAÚDE CITADOS ACIMA
De acordo com a resolução 1931/2009 do Conselho Federal de Medicina e com a RDC 96/2008 da ANVISA, declaro que recebi honorários da Gilead para esse evento.
Referências:
Bula professional TRODELVY; Hugo R, et al. Primary results from TROPiCS-02: A randomized phase 3 study of Sacituzumb Govitecan vs. treatment of physician’s choice in patients with HR-positive/HER2-negative advanced breast cancer. ASCO 202; Hugo R, et al. Overall survival results from the phase 3 TROPiCS-02 study of Sacituzumab Govitecan vs. treatment of physician’s choice in patients with HR-positive/HER2-negative metastatic breast cancer. ESMO 2022; Tolaney SM, et al. Final Overall survival analysis from the phase 3 TROPiCS-02 study of Sacituzumab Govitecan in patients with HR-positive/HER2-negative metastatic breast cancer. ASCO 2023.
Os conteúdos acima são exclusivos aos profissionais de saúde habilitados a dispensar ou prescrever medicamentos.
